Federal cannabis policy took a historic and significant step forward on April 23 when the Department of Justice announced Acting Attorney General Todd Blanche signed a final order placing two specific categories of marijuana — FDA-approved drug products containing marijuana, and marijuana subject to a qualifying state medical marijuana license — into Schedule III of the Controlled Substances Act. The order is effective immediately.
But the move is narrower than many industry observers expected. The final order does not reschedule all marijuana. Adult-use cannabis, unlicensed bulk marijuana, and marijuana extracts not tied to an FDA-approved product or a state medical license remain in Schedule I. Instead, those categories are now subject to a separate, expedited administrative hearing process scheduled to convene on June 29 and conclude no later than July 15.
In other words: what the Department of Justice has delivered is not one rescheduling action, but the beginning of two parallel tracks with very different legal authorities, very different timelines, and, for dual-licensed state operators, some very thorny operational questions.
What the Final Order Actually Does
The final order leans on a specific and somewhat unusual legal authority: 21 U.S.C. § 811(d)(1), which directs the Attorney General to schedule (or reschedule) substances as needed to satisfy U.S. obligations under international drug treaties, most notably the 1961 Single Convention on Narcotic Drugs. Critically, this authority bypasses the normal notice-and-comment rulemaking procedures of § 811(a) and (b) and does not require an HHS scientific and medical evaluation (though, as the order notes, HHS provided one anyway in August 2023 recommending Schedule III).
Because § 811(d)(1) is tethered to treaty obligations, which in turn limit cannabis use “exclusively to medical and scientific purposes,” the order’s reach is necessarily constrained to the medical context. That is why only state-licensed medical marijuana and FDA-approved products made the cut, and why adult-use cannabis requires a separate legal pathway altogether.
The order is explicit on this point:
“Any form of marijuana other than in an FDA-approved drug product or marijuana subject to a state medical marijuana license remains a schedule I controlled substance.” (pg. 18)
That sentence should be the starting point for every conversation operators and investors have in the coming weeks.
A New Federal Registration Pathway for State-Licensed Medical Operators
The most operationally significant element of the final order is a new expedited federal registration process for state-licensed medical marijuana entities. For the first time, state medical marijuana manufacturers, distributors, and dispensers can become federally registered to handle a Schedule III controlled substance without first having to clear the full gauntlet of DEA’s standard application review.
From the order:
“The proposed amendments to Part 1301 establish a new registration pathway for state-licensed medical marijuana entities seeking federal DEA registration as manufacturers, distributors, and/or dispensers. The regulation creates an expedited review process under which applicants holding state medical marijuana licenses may submit their existing state credentials as conclusive evidence of state-law authorization … early applicants may lawfully operate under their state-issued licenses during the pendency of review.” (pg. 21)
Practically, this means:
- Applications submitted within 60 days of publication must be processed within six months.
- A state-issued medical marijuana license is treated as conclusive evidence of state-law authorization for purposes of DEA registration.
- Early applicants can continue operating under state authority while DEA review is pending — no operational gap.
- State-law labeling, packaging, disposal, and physical-security requirements can substitute for federal requirements (with one carve-out: the statutory warning label required under 21 U.S.C. § 825(c) must still appear).
- If the underlying state license is suspended, revoked, or expires, the federal DEA registration is automatically suspended as well.
This is a meaningful federalism move. It effectively incorporates state medical licensing infrastructure into the federal registration system rather than forcing operators through a parallel and duplicative review. DEA retains authority to deny or revoke registration for public-interest reasons or for non-compliance with the Single Convention, but the default presumption runs toward approval.
Single Convention Compliance: DEA Becomes a (Nominal) Market Participant
To keep the United States aligned with its treaty obligations, the order establishes an unusual compliance mechanism under Article 23 of the Single Convention, which requires a government agency to serve as the exclusive purchaser of cannabis production:
“To address Single Convention compliance under Article 23, the rule establishes a nominal price purchase-and-resale mechanism through which the Administration acquires and resells registered manufacturers’ marijuana crops, thereby satisfying the Convention’s requirement that a government agency serve as the exclusive purchaser of cannabis production.” (pg. 22)
In practice, DEA will purchase registered manufacturers’ marijuana crops at a nominal price and resell them back to the same entity (or a related entity) at that same price plus an administrative fee. Registrants must store crops in a DEA-accessible facility until the transaction is complete, and each manufacturer registration must specify the areas in which cultivation is permitted.
Whether this machinery works smoothly in practice, particularly at the scale of existing state medical markets, is an open question and one worth watching. The order is silent on logistical specifics that industry will need to navigate quickly.
Tax Treatment: The End of 280E (for Medical Operators)
One of the most consequential, and most widely anticipated, downstream effects of Schedule III placement is the inapplicability of Internal Revenue Code Section 280E, which disallows ordinary business deductions for any trade or business “trafficking in controlled substances … in schedule I or II.” Because the order places qualifying medical marijuana in Schedule III, Section 280E no longer applies to those activities.
The order goes a step further and encourages retrospective relief:
“The Administrator encourages the Secretary of the Treasury to consider providing retrospective relief from Section 280E liability for taxable years in which a state licensee operated under a state medical marijuana license. Nothing in this rule constitutes a determination regarding federal tax liability …” (pg. 23)
The order is careful to disclaim any binding tax effect, and operators should consult tax counsel about their specific facts. But the policy signal is significant, and it comes as the cannabis industry has paid an estimated $15 billion in excess 280E-related taxes since 2018.
Important caveat: In states where adult-use and medical marijuana operate under dual licenses, often with commingled inventory and shared books, the 280E relief becomes genuinely complicated. Only the medical side of a dual-licensed operation qualifies. Operators who cannot cleanly separate their medical inventory, sales, and records from their adult-use activities may find themselves unable to claim the relief they were expecting. In states like Arizona, where a product’s medical-versus-adult-use designation isn’t determined until the point of sale, this creates immediate accounting and compliance pressure.
The Severability Provision — a Signal That Litigation Is Coming
DEA plainly anticipates legal challenges, and the order includes a severability clause that is worth reading closely:
“It is DEA’s intention that the provisions of this final order shall operate independently of each other. If this final order, or any portion of this final order, is ultimately declared invalid or stayed as to a particular provision, it is DEA’s intent that the final order nonetheless be severable and remain valid with respect to those provisions not affected by a declaration of invalidity or stayed.” (footnote 39)
That kind of clause doesn’t appear by accident. Opponents of rescheduling, most notably Smart Approaches to Marijuana, have already signaled they intend to seek injunctive relief. A particular point of legal vulnerability is not the scheduling action itself (which enjoys a relatively clear statutory basis under § 811(d)(1)) but the operational and registration regulations that accompany it. Whether the treaty-compliance authority extends to the substantial regulatory architecture DEA has built around it will likely be a central issue in any litigation.
The severability clause is DEA’s effort to ensure that if a court strikes down one component, say, the expedited registration pathway, or the nominal-price purchase mechanism, the broader Schedule III placement survives.
How We Got Here
This action follows President Donald Trump’s December 2025 executive order directing federal agencies to expeditiously reschedule marijuana to Schedule III. Marijuana has been classified as a Schedule I substance for decades despite widespread adoption of state-regulated medical marijuana and adult-use marijuana markets.
Rescheduling of marijuana has been underway since the Biden Administration. In 2023, the Department of Health and Human Services formally recommended rescheduling marijuana after concluding that it has a currently accepted medical use. However, the administrative hearings on the proposal to federally reschedule marijuana were postponed earlier this year due to an interlocutory appeal, following allegations that the DEA inappropriately engaged in ex parte communications with opponents of rescheduling. DOJ and DEA are withdrawing prior hearing proceedings from 2024 to expedite a revised process with new deadlines.
Schedule III status recognizes accepted medical use, allows businesses to claim standard business deductions currently disallowed by 280E, and reduces barriers to scientific and medical research. It does not change federal criminal laws and penalties.
What Rescheduling Does Not Do
It’s worth being clear about the things this final order does not accomplish:
- It does not legalize marijuana at the federal level. Possession, cultivation, distribution, and sale of marijuana outside the covered medical categories remain federal crimes.
- It does not affect anyone currently incarcerated on federal marijuana charges.
- It does not cover adult-use (recreational) marijuana, even in states where it is legal.
- It does not apply to synthetically derived THC (such as delta-10-tetrahydrocannabinol), which remains in Schedule I.
- It does not alter the legal status of hemp as defined in 7 U.S.C. § 1639o, though a separate statutory change to the hemp definition takes effect November 12, 2026.
- It does not change SAFE Banking, interstate commerce restrictions, or the federal-state conflict for adult-use operators.
Next Steps and What Stakeholders Should Know
The practical implications of the rescheduling order remain uncertain, particularly for businesses involved in both medical and adult-use activities. The DEA is expected to publish a new hearing notice in the Federal Register to “fully remove marijuana from Schedule I and place it into Schedule III under the Controlled Substances Act.” The anticipated timeline has been released for the new administrative hearings:
- The new hearing will convene on June 29, 2026, and will conclude no later than July 15, 2026.
- Every “interested person” who wishes to participate in the hearing will need to file a written notice of intention to participate on or before May 24, 2026.
- Interested persons selected to participate will be notified on June 22, 2026.
That is a compressed timeline by administrative hearing standards, a signal that DOJ and DEA intend to move decisively, and an opportunity for stakeholders who want a seat at the table to prepare their filings now.
Takeaways for Operators, Investors, and Policymakers
A few observations as the dust settles:
- State medical marijuana operators should evaluate the expedited registration pathway now. The 60-day application window matters: filing within it triggers the six-month processing deadline and allows lawful operation under state authority during DEA review. Operators who wait risk losing that bridging protection.
- Dual-licensed operators face real operational pressure. If a single facility handles both medical and adult-use inventory under a single set of books, the medical-only benefits of Schedule III placement, including 280E relief and federal DEA registration, may be difficult to capture cleanly. Now is the time to assess whether operations, inventory, and accounting can be segregated.
- The June 29 hearing is where the broader question gets decided. Whether adult-use marijuana ultimately moves to Schedule III depends on that administrative process and any subsequent litigation. Stakeholders with a view on the outcome should consider whether to file a notice of intent to participate by May 24.
- Litigation risk is real and acknowledged. DEA’s severability provision is a tell. Expect at least one court challenge to the operational and registration components of the order in the coming weeks.
- This is still not legalization, and it is not a fix for the two-track problem. Federal criminal law continues to apply to non-covered marijuana activity. The continued fragmentation between “medical” and “adult-use,” and between marijuana and hemp, remains the most significant structural flaw in federal cannabis policy. Today’s action narrows that fragmentation in one direction while preserving it in another.
We will continue to track developments, including the Federal Register hearing notice, any legal challenges filed against the final order, Treasury guidance on retrospective 280E relief, and the progression of the June 29 hearing process, and will share updates as they emerge.
